The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.

@article{Belani2010TheRO,
  title={The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.},
  author={Chandra Prakash Belani},
  journal={Cancer investigation},
  year={2010},
  volume={28 4},
  pages={
          413-23
        }
}
  • Chandra Prakash Belani
  • Published 2010
  • Medicine
  • Cancer investigation
  • Reversible epidermal growth factor receptor tyrosine kinase inhibitors are often used for the treatment of non-small cell lung cancer following failure of cytotoxic chemotherapy. While these agents are active in a subset of patients, most develop resistance and progress within the course of 1 year. In nearly half of the cases, acquired resistance is caused by a secondary epidermal growth factor receptor T790M mutation. Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 38 CITATIONS, ESTIMATED 43% COVERAGE

    Gefitinib in Non Small Cell Lung Cancer

    VIEW 1 EXCERPT
    CITES BACKGROUND

    EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Novel therapeutic targets in non-small cell lung cancer.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2010
    2020

    CITATION STATISTICS

    • 1 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 88 REFERENCES

    Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Defining clinically relevant molecular subsets of lung cancer

    • William Pao
    • Medicine
    • Cancer Chemotherapy and Pharmacology
    • 2006
    VIEW 1 EXCERPT